UPDATED. Boosts effectiveness by 44.4%% of commercially available Covid antibody in cocktail Jackson Center, PA November 30, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.” The article has been peer ...
Boosts Effectiveness of Commercial Covid Antibodies by 45% Jackson Center, PA, July 14, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulation, including Omicron. When Halberd’s antibody was combined with a leading commercially available Covid-19 antibody in an antibody cocktail, effectiveness ...
Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies. The results are shown ...
Demonstrates Greater Binding Affinity Than Previous Antibodies Jackson Center, PA, June 7, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful creation of two new neutralizing antibodies against the Spike Protein of SARS-CoV-2, both with a stronger binding affinity than Halberd’s earlier announced monoclonal antibodies against Covid-19. Each of these new antibodies bind to different ...
Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein. This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy ...
Paves Way for Disease Elimination by Radio Frequency Waves Jackson Center, PA, March 30, 2021 – Halberd Corporation (OTC-PINK: "HALB") has successfully conjugated (joined) metallic nanoparticles with its patent-pending SARS-CoV-2 antibody, while still maintaining the antibody’s antigen-neutralizing properties. This was a key scientific hurdle to overcome in implementing its patent-pending extracorporeal disease eradication methodology through ...
Jackson Center, PA, March 9, 2021 – Halberd Corporation’s (OTC PINK:HALB) Chairman, President & CEO, William A. Hartman, was interviewed recently on The Stock Day Podcast, hosted by Everett Jolly. In the interview, Mr. Hartman reviewed the company’s progress in developing SARS-CoV-2 spike protein antibodies and how they can be combined with other Halberd technologies ...
Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which ...
Jackson Center, PA, December 23, 2020 – Halberd Corp. (OTC PINK: "HALB") research has produced a second monoclonal antibody (mAb) against the Covid-19 spike protein. Initial testing displays a stronger affinity for the SARS-CoV-2 antigen than Halberd’s initial antibody. Testing continues through the holidays on each antibody to establish potency and specificity (i.e., targets only ...
Jackson Center, PA, December 14, 2020 – Halberd Corporation (OTC PINK: "HALB") announced its proprietary, highly potent, neutralizing antibody against SARS-CoV-2, which demonstrated very strong receptor specificity and inhibition of SARS-CoV-2 replication. Halberd’s anti-Spike protein monoclonal antibody, recently filed with the United States Patent Office, underwent in vitro studies at Arizona State University (ASU). Based ...